One in eight people (12%) starting antiretroviral treatment in a South African clinic would have been unable to benefit from injectable treatment that includes rilpivirine due to pre-existing resistance to the drug, South African researchers report.
In people experiencing failure of a non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, rilpivirine resistance was widespread. Close to half (44%) had high-level resistance to rilpivirine and overall, three-quarters showed some degree of resistance to rilpivirine.
Read the full story at Aidsmap.
Source : Aidsmap
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.